Diversigen will serve as a central lab for the

Diversigen will serve as a central lab for the generation of high quality microbiome data to be incorporated into the Crohn’s & Colitis Foundation’s IBD Plexus® platform

HOUSTON, TX — Diversigen Inc. is pleased to announce that the company has been selected by the Crohn’s & Colitis Foundation as a preferred provider for metagenomics and microbiome analysis services and to serve as a central lab for the generation of high quality microbiome data to be incorporated into the IBD Plexus® platform. IBD Plexus is a first-of-its-kind research information exchange platform designed to centralize data and bio samples from diverse research initiatives to advance science, accelerate precision medicine, and transform the care of IBD patients. This partnership will allow academic and industry researchers to take advantage of Diversigen high quality CLIA/CAP microbiome analytical capabilities, ensuring that the same protocols and analytical pipelines are used is a crucial component to create uniform and reproducible datasets.

“Through our partnership with Diversigen, we are converting finite biosamples into reusable assets that will enable researchers across the country to not only gain expedited access to molecular data but also leverage uniform datasets across projects, ultimately generating a critical mass of information necessary to advance the science,” said Angela Dobes, MPH, Senior Director IBD Plexus. 

“We are very excited to be able to work with the Crohn’s & Colitis Foundation on this important endeavor. Engaging large cohorts with optimized standard practices is fundamentally critical for discovery in translational microbiome research. The inclusion of such data into the IBD Plexus® platform is a model for research across many areas of disease. We are pleased that the Foundation recognized Diversigen’s deep commitment to quality across the entire microbiome pipeline and our continual investment in process and analytical innovation,” said Dr. Joseph Petrosino, Founder and Chief Scientific Officer of Diversigen, Inc.

About Diversigen Inc.

Diversigen, Inc. is a Baylor College of Medicine portfolio company.  The company provides consultative end-to-end solutions for sequencing, bioinformatics and statistical analysis for the study of the microbiome of living organisms and environments.  Diversigen, Inc. operates a state-of-the-art CLIA/CAP accredited laboratory deploying a variety of techniques to extract high quality nucleic acids from a multitude of sample types for subsequent metagenomics analysis. Diversigen’s flexible sequencing and computing capacity, combined with ongoing improvements in analytic tools and their applications, allows for customized project-specific strategies.

For more information, visit www.diversigen.com or contact info@diversigen.com.